LBA: Acalabrutinib plus Bendamustine and Rituximab Show Significant Improvement in PFS for Elderly Patients with Mantle Cell Lymphoma

Michael Wang, from the MD Anderson Cancer Center, presents in this MEDtalk the results of his late-breaking abstract at EHA 2024. The study shows a statistically significant improvement in PFS with acalabrutinib combined with bendamustine and rituximab for elderly patients with untreated mantle cell lymphoma, which might become the new standard of care. In addition, Dr. Wang praises the Nordic study group on mantle cell lymphoma.